• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诊断时年龄、肿瘤大小和阳性淋巴结数的非线性变换对乳腺癌临床结局的预测。

Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer.

机构信息

Faculty of Medicine, Department of Clinical Sciences Lund, Oncology and Pathology, Lund University, Medicon Village Building 404, Scheelevägen 2, SE-223 81, Lund, Sweden.

Department of Pathology, Odense University Hospital, DK-5000, Odense, Denmark.

出版信息

BMC Cancer. 2018 Dec 7;18(1):1226. doi: 10.1186/s12885-018-5123-x.

DOI:10.1186/s12885-018-5123-x
PMID:30526533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6286551/
Abstract

BACKGROUND

Prognostic factors in breast cancer are often measured on a continuous scale, but categorized for clinical decision-making. The primary aim of this study was to evaluate if accounting for continuous non-linear effects of the three factors age at diagnosis, tumor size, and number of positive lymph nodes improves prognostication. These factors will most likely be included in the management of breast cancer patients also in the future, after an expected implementation of gene expression profiling for adjuvant treatment decision-making.

METHODS

Four thousand four hundred forty seven and 1132 women with primary breast cancer constituted the derivation and validation set, respectively. Potential non-linear effects on the log hazard of distant recurrences of the three factors were evaluated during 10 years of follow-up. Cox-models of successively increasing complexity: dichotomized predictors, predictors categorized into three or four groups, and predictors transformed using fractional polynomials (FPs) or restricted cubic splines (RCS), were used. Predictive performance was evaluated by Harrell's C-index.

RESULTS

Using FP-transformations, non-linear effects were detected for tumor size and number of positive lymph nodes in univariable analyses. For age, non-linear transformations did, however, not improve the model fit significantly compared to the linear identity transformation. As expected, the C-index increased with increasing model complexity for multivariable models including the three factors. By allowing more than one cut-point per factor, the C-index increased from 0.628 to 0.674. The additional gain, as measured by the C-index, when using FP- or RCS-transformations was modest (0.695 and 0.696, respectively). The corresponding C-indices for these four models in the validation set, based on the same transformations and parameter estimates from the derivation set, were 0.675, 0.700, 0.706, and 0.701.

CONCLUSIONS

Categorization of each factor into three to four groups was found to improve prognostication compared to dichotomization. The additional gain by allowing continuous non-linear effects modeled by FPs or RCS was modest. However, the continuous nature of these transformations has the advantage of making it possible to form risk groups of any size.

摘要

背景

乳腺癌的预后因素通常在连续尺度上进行测量,但为了临床决策而进行分类。本研究的主要目的是评估是否考虑到诊断时年龄、肿瘤大小和阳性淋巴结数量这三个因素的连续非线性效应可以改善预后。这些因素很可能在未来也将被纳入乳腺癌患者的管理中,因为预计在做出辅助治疗决策时会采用基因表达谱分析。

方法

4447 名和 1132 名原发性乳腺癌患者分别构成了推导集和验证集。在 10 年的随访期间,评估了这三个因素对远处复发对数风险的潜在非线性效应。使用 Cox 模型的复杂度依次增加:将预测因子二分类、将预测因子分类为三或四组、使用分数多项式(FP)或限制立方样条(RCS)对预测因子进行转换。使用 Harrell 的 C 指数评估预测性能。

结果

使用 FP 转换,在单变量分析中检测到肿瘤大小和阳性淋巴结数的非线性效应。对于年龄,与线性恒等转换相比,非线性转换并没有显著改善模型拟合度。正如预期的那样,对于包含三个因素的多变量模型,随着模型复杂性的增加,C 指数也随之增加。通过允许每个因素有多个截断点,C 指数从 0.628 增加到 0.674。使用 FP 或 RCS 转换时,C 指数的额外增益适中(分别为 0.695 和 0.696)。在验证集中,基于推导集中相同的转换和参数估计,这些四个模型的 C 指数分别为 0.675、0.700、0.706 和 0.701。

结论

将每个因素分为三到四个组比二分类更能提高预后。通过允许 FP 或 RCS 对连续非线性效应进行建模,获得的额外增益适中。然而,这些转换的连续性质具有可以形成任何大小的风险组的优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/9886ab633b90/12885_2018_5123_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/f55a70adceec/12885_2018_5123_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/42f9907f74a7/12885_2018_5123_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/15613327e2e1/12885_2018_5123_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/835662b20327/12885_2018_5123_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/9886ab633b90/12885_2018_5123_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/f55a70adceec/12885_2018_5123_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/42f9907f74a7/12885_2018_5123_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/15613327e2e1/12885_2018_5123_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/835662b20327/12885_2018_5123_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafb/6286551/9886ab633b90/12885_2018_5123_Fig5_HTML.jpg

相似文献

1
Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer.诊断时年龄、肿瘤大小和阳性淋巴结数的非线性变换对乳腺癌临床结局的预测。
BMC Cancer. 2018 Dec 7;18(1):1226. doi: 10.1186/s12885-018-5123-x.
2
Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes.有 1-3 个阳性腋窝淋巴结的乳腺癌患者区域淋巴结复发的风险因素。
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2093-103. doi: 10.1016/j.ijrobp.2011.01.066. Epub 2011 Apr 27.
3
The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.在有1至3个腋窝淋巴结阳性的乳腺癌患者中,阳性/切除腋窝淋巴结百分比对复发和生存的预后意义。
Cancer. 2005 May 15;103(10):2006-14. doi: 10.1002/cncr.20969.
4
[Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].10枚及以上阳性淋巴结的女性乳腺癌患者的临床特征及预后因素:128例报告
Zhonghua Yi Xue Za Zhi. 2008 Jan 8;88(2):77-81.
5
Ratios of involved nodes in early breast cancer.早期乳腺癌中受累淋巴结的比例。
Breast Cancer Res. 2004;6(6):R680-8. doi: 10.1186/bcr934. Epub 2004 Oct 6.
6
The prognostic significance of nodal ratio on breast cancer recurrence and its potential for incorporation in a new prognostic index.淋巴结比率对乳腺癌复发的预后意义及其在新预后指标中的潜在应用。
Breast J. 2013 Jul-Aug;19(4):388-93. doi: 10.1111/tbj.12122. Epub 2013 May 31.
7
Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.影响三阴性乳腺癌患者生存的临床和病理因素的大样本研究。
BMC Cancer. 2018 Jan 8;18(1):56. doi: 10.1186/s12885-017-3969-y.
8
The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.淋巴结比率作为非转移性淋巴结阳性乳腺癌复发和死亡率的独立预后因素。
J BUON. 2015 May-Jun;20(3):737-45.
9
Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.新辅助化疗的临床和病理反应与局部晚期乳腺癌预后的关系
J Surg Oncol. 2002 May;80(1):4-11. doi: 10.1002/jso.10090.
10
Prognostic factors of young women (≤ 35 years) with node positive breast cancer: possible influence on post-therapeutic follow-up.≤35岁的淋巴结阳性乳腺癌年轻女性的预后因素:对治疗后随访的可能影响
Bull Cancer. 2013 Jul-Aug;100(7-8):22-9. doi: 10.1684/bdc.2013.1791.

引用本文的文献

1
Diagnostic performance of ultrasound S-Detect technology in evaluating BI-RADS-4 breast nodules ≤ 20 mm and > 20 mm.超声S-Detect技术在评估直径≤20mm和>20mm的BI-RADS-4类乳腺结节中的诊断性能
BMC Cancer. 2025 Aug 12;25(1):1306. doi: 10.1186/s12885-025-14760-2.
2
The Prognostic Value of Serum Albumin to Globulin Ratio in Patients with Breast Cancer: A Retrospective Study.血清白蛋白与球蛋白比值在乳腺癌患者中的预后价值:一项回顾性研究。
Breast Cancer (Dove Med Press). 2024 Jul 25;16:403-411. doi: 10.2147/BCTT.S471747. eCollection 2024.
3
A Prognostic Model to Assess Long-Term Survival of Patients on Antiretroviral Therapy: A 15-Year Retrospective Cohort Study in Southwestern China.

本文引用的文献

1
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.降阶梯和升阶梯治疗早期乳腺癌:2017 年圣加仑国际早期乳腺癌专家共识会议关于早期乳腺癌的主要治疗。
Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308.
2
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.利用生物标志物指导早期浸润性乳腺癌女性辅助性全身治疗决策:美国临床肿瘤学会临床实践指南
J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8.
3
评估接受抗逆转录病毒治疗患者长期生存情况的预后模型:中国西南部一项15年的回顾性队列研究
Open Forum Infect Dis. 2021 Jun 12;8(7):ofab309. doi: 10.1093/ofid/ofab309. eCollection 2021 Jul.
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
乳腺癌试验中事件发生时间终点定义指南:DATECAN倡议(癌症试验中事件发生时间终点评估定义)的结果
Ann Oncol. 2015 Dec;26(12):2505-6. doi: 10.1093/annonc/mdv478. Epub 2015 Oct 13.
4
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.定制疗法——改善早期乳腺癌的管理:2015年早期乳腺癌初始治疗圣加仑国际专家共识
Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4.
5
Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.仅接受雌激素受体阳性乳腺癌辅助内分泌治疗的绝经后高危女性的超额死亡率。
Acta Oncol. 2014 Feb;53(2):174-85. doi: 10.3109/0284186X.2013.850738. Epub 2013 Nov 13.
6
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.个体化治疗早期乳腺癌女性:2013 年圣加仑国际早期乳腺癌专家共识初级治疗要点。
Ann Oncol. 2013 Sep;24(9):2206-23. doi: 10.1093/annonc/mdt303. Epub 2013 Aug 4.
7
Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.在原发性乳腺癌患者中,进行了 10 年随访,检测了原发肿瘤、同期淋巴结转移和异时性复发中生物标志物的表达和圣加仑分子亚型分类。
Breast Cancer Res Treat. 2013 Jul;140(1):93-104. doi: 10.1007/s10549-013-2617-8. Epub 2013 Jun 27.
8
Training artificial neural networks directly on the concordance index for censored data using genetic algorithms.利用遗传算法直接在删失数据的一致性指数上训练人工神经网络。
Artif Intell Med. 2013 Jun;58(2):125-32. doi: 10.1016/j.artmed.2013.03.001. Epub 2013 Apr 10.
9
External validation of a Cox prognostic model: principles and methods.Cox 预后模型的外部验证:原则与方法。
BMC Med Res Methodol. 2013 Mar 6;13:33. doi: 10.1186/1471-2288-13-33.
10
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.报告肿瘤标志物预后研究建议(REMARK):解释和说明。
BMC Med. 2012 May 29;10:51. doi: 10.1186/1741-7015-10-51.